Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Bladder Cancer: early-phase trial registry
74 of 179 indexed Bladder Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #61 of 28,707 conditions by registered trial count.
179 US clinical trials · 74 currently recruiting · #61 of 28,707 conditions by registered trial count
Bladder Cancer: 179 US clinical trials tracked, 74 recruiting.
Bladder Cancer is the subject of 179 registered US clinical trials on ClinicalTrials.gov, 74 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 17 of these trials.
Enrollment posture brief
Registry condition bladder-cancer
OPEN 74 | RECR 41% | LATE 14 | EARLY 84 | RANK #61 | SPON 17
Volume-matched condition peers
Nearest open-share peer: Pediatric Obesity (41% recruiting · 46 trials)
Bladder Cancer lists 74 open slots (41% of 179 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Bladder Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Bladder Cancer is recruiting above its size-band peers.
74 of 179 indexed trials (41.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Bladder Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 17 of 179 trials (9.5%). 92 distinct sponsors appear on at least one study for this condition label.
-
Typical Bladder Cancer enrolment sits around 98 participants.
Median target enrolment is 98 among the 176 trials that report a genuine target (sentinel values excluded). 90 of those (51.1%) plan for fewer than 100 participants.
-
Bladder Cancer research is mostly interventional.
131 interventional and 48 observational studies make up this index (73.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
179 total, page 1 of 4
Evaluation for NCI Surgery Branch Clinical Research Protocols
National Cancer Institute (NCI)
NCT00001823
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Adela
NCT05366881
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
National Cancer Institute (NCI)
NCT00026884
Blue Light Cystoscopy With Cysview® Registry
Photocure
NCT02660645
Measuring Surgical Recovery After Radical Cystectomy
M.D. Anderson Cancer Center
NCT03193970
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Elephas
NCT07327489
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
National Cancer Institute (NCI)
NCT04923178
Bladder Cancer Screening Trial
University of Texas Southwestern Medical Center
NCT05646485
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers
University of Kansas Medical Center
NCT03413982
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
University of California, San Francisco
NCT05056077
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Cedars-Sinai Medical Center
NCT03193541
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT06172478
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
NCT07129993
A Study of Surgical Techniques During Cystectomy
Memorial Sloan Kettering Cancer Center
NCT06703476
Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Early is Good
NCT05982561
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
UNC Lineberger Comprehensive Cancer Center
NCT06896162
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
National Cancer Institute (NCI)
NCT02379429
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Elephas
NCT05520099
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
University of Washington
NCT07225127
Predicting BCG Response
Cedars-Sinai Medical Center
NCT04564781
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
NCT04916990
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT06503146
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT07090499
A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer
Cedars-Sinai Medical Center
NCT03193515
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
NCT07277413
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
NCT06242470
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Totus Medicines
NCT05683418
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Johns Hopkins University
NCT06525571
Comprehensive Optimization At-time of Radical Cystectomy Intervention
University of Texas Southwestern Medical Center
NCT05714826
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Dana-Farber Cancer Institute
NCT06138561
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine
NCT06022029
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United
NCT07217171
Telehealth Intervention for Ostomy Self-Management
City of Hope Medical Center
NCT06528990
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
NCT07030257
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
NCT07050771
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Brigham and Women's Hospital
NCT03216525
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
Johns Hopkins University
NCT07225205
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
University of Washington
NCT06040762
Sacituzumab Govitecan Plus EV in Metastatic UC
Dana-Farber Cancer Institute
NCT04724018
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
NCT06973161
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Cancer Institute (NCI)
NCT04235777
DESTINY-PANTUMOUR04
AstraZeneca
NCT07124000
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
University of Chicago
NCT06427824
Gender Related Coping and Survivorship for Genitourinary Cancers
Johns Hopkins University
NCT05649306
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Brigham and Women's Hospital
NCT04368702
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
Thomas Jefferson University
NCT07234968
Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
Johns Hopkins University
NCT05792722
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05312671
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Cedars-Sinai Medical Center
NCT04442724
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Merck Sharp & Dohme
NCT07232602
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 45 |
| Phase 3 | 14 |
Top Sponsors
Named interventions
Most-linked intervention names on Bladder Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Bladder Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Bladder Cancer page
179 registered trials, 74 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 74 Bladder Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Bladder Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bladder Cancer condition card totals 179 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.